Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Retatrutide has generated significant and rapidly expanding research interest as the first tri-receptor incretin agonist to reach advanced pre-clinical and clinical investigation: Triple Receptor Mechanism: Research has characterised Retatrutides balanced activity across GLP-1R, GIPR, and GCGR, with studies documenting its receptor binding affinities, downstream signalling characteristics at each receptor, and the combined metabolic profile produced by tri-agonist co-stimulation confirming a pharmacological profile that is fundamentally broader than any dual or single-receptor compound
Duality of interest The authors declare that there is no duality of interest associated with this manuscript
The FDA-approved oral formulation (Rybelsus for diabetes, Wegovy pill for weight loss) has been clinically validated but requires much higher doses than injectable versions
One example is the retatrutide injection kit: The substance contained in the kit is still in clinical development and is not authorised internationally
Vomiting (the third most commonly reported side effect) Stay hydrated
US$ 24.46
US$ 21.57
US$ 27.88
US$ 21.15
